indazoles has been researched along with Bile Duct Cancer in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aravantinos, G; Demiri, S; Fountzilas, G; Koliou, GA; Lampropoulou, DI; Pectasides, D; Pentheroudakis, G; Psyrri, A; Razis, E; Samantas, E; Sgouros, J; Zagouri, F | 1 |
| Brandi, G; Rizzo, A | 1 |
| Azad, NS; Gallagher, D; O'Connor, A; Ohaji, C; Rosner, G; Sartorius-Mergenthaler, S; Shroff, RT; Subbiah, V; Yarchoan, M; Zahurak, ML; Zinner, R | 1 |
| Bronk, SF; Gores, GJ; Hernandez, MC; Hirsova, P; Kabashima, A; Kaufmann, SH; Rizvi, S; Truty, MJ | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Furukawa, H; Furuse, J; Ojima, H; Shibata, T; Shimizu, H; Takahashi, H | 1 |
| Barat, S; Bozko, P; Chen, X; Götze, J; Hanert, F; Malek, NP; Plentz, RR; Scholta, T; Wilkens, L | 1 |
| Boonmars, T; Cha'on, U; Phoomak, C; Sangkhamanon, S; Seubwai, W; Thamrongwaranggoon, U; Wongkham, S | 1 |
1 trial(s) available for indazoles and Bile Duct Cancer
| Article | Year |
|---|---|
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
7 other study(ies) available for indazoles and Bile Duct Cancer
| Article | Year |
|---|---|
TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks.
Topics: Benzamides; Bile Duct Neoplasms; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Indazoles; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2021 |
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Disease Progression; Disease-Free Survival; Drug Eruptions; Exanthema; Female; Humans; Hypertension; Indazoles; Male; MAP Kinase Kinase Kinases; Middle Aged; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrimidinones; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Survival Rate; Thrombocytopenia | 2017 |
Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cell Death; Cell Line, Tumor; Cholangiocarcinoma; Humans; Indazoles; Indoles; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Necrosis; Oxidation-Reduction; Receptors, Fibroblast Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Axitinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Imidazoles; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Female; Humans; Indazoles; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Niacinamide; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction | 2016 |
Targeting hexokinase II as a possible therapy for cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; Cricetinae; Disease Progression; Enzyme Inhibitors; Hexokinase; Immunohistochemistry; Indazoles; Opisthorchis | 2017 |